Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.6.99.6 (
NADPH oxidase
)
10,295
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Activation of D1-like receptors (D1 and/or D5) induces antioxidant responses; however, the mechanism(s) involved in their antioxidant actions are not known. We hypothesized that stimulation of the D5 receptor inhibits
NADPH oxidase
activity, and thus the production of reactive oxygen species (ROS). We investigated this issue in D5 receptor-deficient (D5-/-) and wild-type (D5+/+) mice.
NADPH oxidase
protein expression (gp91(phox), p47(phox), and Nox 4) and activity in kidney and brain, as well as plasma thiobarbituric acid-reactive substances (TBARS) were higher in D5-/- than in D5+/+ mice. Furthermore, apocynin, an
NADPH oxidase
inhibitor, normalized blood pressure, renal NADPH oxidase activity, and plasma TBARS in D5-/- mice. In HEK-293 cells that heterologously expressed human D5 receptor, its agonist fenoldopam decreased
NADPH oxidase
activity, expression of one of its subunits (gp91(phox)), and ROS production. The inhibitory effect of the D5 receptor activation on
NADPH oxidase
activity was independent of cAMP/PKA but was partially dependent on
phospholipase D2
. The ability of D5 receptor stimulation to decrease ROS production may explain, in part, the antihypertensive action of D5 receptor activation.
...
PMID:D5 dopamine receptor regulation of reactive oxygen species production, NADPH oxidase, and blood pressure. 1635 63
We have recently shown that the activation of the rat mu-opioid receptor (MOPr, also termed MOR1) by the mu-agonist [D-Ala(2), Me Phe(4), Glyol(5)]enkephalin (DAMGO) leads to an increase in
phospholipase D2
(
PLD2
) activity and an induction of receptor endocytosis, whereas the agonist morphine which does not induce opioid receptor endocytosis fails to activate
PLD2
. We report here that MOPr-mediated activation of
PLD2
stimulates production of reactive oxygen molecules via NADH/
NADPH oxidase
. Oxidative stress was measured with the fluorescent probe dichlorodihydrofluorescein diacetate and the role of
PLD2
was assessed by the PLD inhibitor D-erythro-sphingosine (sphinganine) and by
PLD2
-small interfering RNA transfection. To determine whether NADH/
NADPH oxidase
contributes to opioid-induced production of reactive oxygen species, mu-agonist-stimulated cells were pre-treated with the flavoprotein inhibitor, diphenylene iodonium, or the specific
NADPH oxidase
inhibitor, apocynin. Our results demonstrate that receptor-internalizing agonists (like DAMGO, beta-endorphin, methadone, piritramide, fentanyl, sufentanil, and etonitazene) strongly induce NADH/NADPH-mediated ROS synthesis via PLD-dependent signaling pathways, whereas agonists that do not induce MOPr endocytosis and
PLD2
activation (like morphine, buprenorphine, hydromorphone, and oxycodone) failed to activate ROS synthesis in transfected human embryonic kidney 293 cells. These findings indicate that the agonist-selective
PLD2
activation plays a key role in the regulation of NADH/NADPH-mediated ROS formation by opioids.
...
PMID:mu-opioid receptor-stimulated synthesis of reactive oxygen species is mediated via phospholipase D2. 1951 62
Dopamine, which is synthesized in the kidney, independent of renal nerves, plays an important role in the regulation of fluid and electrolyte balance and systemic blood pressure. Lack of any of the five dopamine receptor subtypes (D1R, D2R, D3R, D4R, and D5R) results in hypertension. D1R, D2R, and D5R have been reported to be important in the maintenance of a normal redox balance. In the kidney, the antioxidant effects of these receptors are caused by direct and indirect inhibition of pro-oxidant enzymes, specifically, nicotinamide adenine dinucleotide phosphate, reduced form (NADPH) oxidase, and stimulation of anti-oxidant enzymes, which can also indirectly inhibit
NADPH oxidase
activity. Thus, stimulation of the D2R increases the expression of endogenous anti-oxidants, such as Parkinson protein 7 (PARK7 or DJ-1), paraoxonase 2 (PON2), and heme oxygenase 2 (HO-2), all of which can inhibit
NADPH oxidase
activity. The D5R decreases
NADPH oxidase
activity, via the inhibition of
phospholipase D2
, and increases the expression of HO-1, another antioxidant. D1R inhibits
NADPH oxidase
activity via protein kinase A and protein kinase C cross-talk. In this review, we provide an overview of the protective roles of a specific dopamine receptor subtype on renal oxidative stress, the different mechanisms involved in this effect, and the role of oxidative stress and impairment of dopamine receptor function in the hypertension that arises from the genetic ablation of a specific dopamine receptor gene in mice.
...
PMID:Renal dopamine receptors, oxidative stress, and hypertension. 2398 27